Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment
Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on ...
Allurion Technologies balloon data ‘intriguing,’ says Chardan
Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...
Allurion Technologies’ gastric balloon+GLP1s may become new SOC, says Roth MKM
Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.
Allurion Shares Surge 40% on Positive Results from Weight-Loss Study
Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...
Morningstar3d
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1 ...
Nasdaq1mon
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous ...
Yahoo Finance19d
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the ...